New guidelines offer guidance on how and when to switch between RA drug classes News-Medical.net Also important are biological agents, which include tumor necrosis factor-inhibitors etanercept and infliximab and non-TNF biologicals abatacept, tocilizumab and rituximab. New since 2008 are the biologics certolizumab pegol, golimumab and tocilizumab, ... |
